| Name | Title | Contact Details |
|---|
Western Veterinary Partners is a veterinary support organization based in Denver, Colorado. Founded in 2019, the company partners with veterinarians across the United States, focusing on enhancing their professional and personal lives while creating a supportive community for veterinary professionals. The organization acquires and affiliates with veterinary practices, primarily in the Western states, to provide non-clinical business support. This allows veterinarians to concentrate on patient care by outsourcing operational tasks. Western Veterinary Partners offers a range of services, including provider recruitment, finance and accounting, marketing, and staffing management. They also provide mentoring and continuing education programs to help expand veterinary knowledge and skills. With a commitment to core values such as integrity and collaboration, Western Veterinary Partners emphasizes respect for practice culture and autonomy. The company has approximately 49 employees and reported revenue of $5.7 million, demonstrating strong growth through strategic acquisitions.
Strategic growth advisor to FinTech and Wealth Management organizations
IVP, a public listed company, was founded in 1929. We started with vegetable oils and later diversified into an array of fields We were originally part of the TATA Group but later got acquired by the Allanas. Today we are an integral part of the Allana Group. We were the first company to manufacture Foundry Chemicals in India in technical collaboration with M/s Ashland Inc way back in 1965 Our manufacturing plants at Tarapur and Bangalore have a combined annual capacity of approximately 50,000 MT per annum catering to the foundry, composites, refractory & insulation industries in India and neighboring countries.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.